Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?

• DOI: 10.1016/j.jimed.2023.03.001
• Publication Date: 2023-05-02T21:18:37Z
• Authors: Naijian Ge; Hongbo Wang; Chengjian He; Xiangdong Wang; Jian Huang; Yefa Yang
• Keywords: 0301 basic medicine; 0302 clinical medicine; Hepatocellular carcinoma; Hepatic artery infusion chemotherapy; R; Medicine; Transcatheter arterial chemoembolization; Article; 3. Good health

Primary liver cancer is a common and lethal malignancy in China. Transcatheter arterial chemoembolization (TACE) is globally recognized as the preferred treatment modality for the non-surgical resection of hepatocellular carcinoma (HCC), while transcatheter arterial infusion (TAI) is another effective interventional treatment for HCC. In recent years, hepatic arterial infusion chemotherapy (HAIC) has gained increasing attention as an application-regulated modality for TAI. Owing to the current debate in the medical community regarding the use of HAIC and TACE for the treatment of HCC, the application of both approaches should be considered at a higher level, with a broader perspective and a more normative aspect. Accordingly, we aimed to define the rational combination of liver cancer TAI/HAIC with TACE as infusion transcatheter chemoembolization (iTACE), which suggests that the two interventions are not superior but lead to a mutually beneficial situation. In this review, we sought to discuss the development, specification, application, challenge and innovation, debate, and union of TAI/HAIC and TACE, and the clinical application and latest research on iTACE. We aimed to introduce new concepts of iTACE and expect new breakthroughs in the treatment of liver cancer owing to the combined use of the two major interventional tools.